UroGen (URGN) - Market Capitalization

Graphic logo of UroGen (URGN)

UroGen Pharma Ltd. (URGN) integrates principles of environmental responsibility and bioethics into the development of oncology treatments, minimizing environmental impact during production. This price trend, where the market capitalization stands at 1.28, complements the business analysis. The company aims to replace complex surgeries with local chemotherapy using slow-release delivery systems, which radically improves the well-being of patients with urothelial cancers.

URGN urogen.com: Market Capitalization in the range 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for urogen.com (URGN)

- market price and analyst price targets:
Fundamental company valuation:UroGen Pharma Corp URGN
Product sample of UroGen Pharma Ltd.

UroGen Pharma Ltd. (URGN) focus on independently launching its drug without M&A activity makes the company's market valuation a direct indicator of confidence in the product's commercial success. This metric, calculated as the product of the current share price and the total number of issued shares, reflects the market consensus on the business value, allowing investors to differentiate sustainable capitalization growth from speculative price spikes.

Competitors of UroGen Pharma Ltd. (URGN)

Market Value BeiGene Ltd ONC|Market Capitalization Halozyme Corp HALO|RVMD - Market Value|Market Valuation AAPG|CG Oncology Corp (CGON) - Market Value|Market Capitalization BCAX|PSNL (Personalis Genomics) - Market Capitalization|Market Valuation Erasca Corp (ERAS)|Market Capitalization DCTH|Market Capitalization ymabs.com (YMAB)|Market Value Aura Bio AURA|CADL: Market Capitalization|Accuray, Inc. - Market Capitalization|Market Value SELLAS Life Sciences Group|ACTU: Market Capitalization|Market Value citiusonc.com (CTOR)|Market Value tuhurabio.com|TARA: Market Value|Market Valuation FATE (Fate Therapeutics Corp)|WHWK (Aadi Bioscience) - Market Value|Market Capitalization TCRX (TScan Therapeutics)|CSBR - Market Valuation|XBIT: Market Valuation|Market Value CVM (cel-sci.com)|OS Therapies Inc (OSTX) - Market Value|Radiopharm Theranostics - Market Value|ARTV (Artiva Biotherapeutics Inc.) - Market Capitalization|Market Capitalization Adlai Nortye Ltd.|Market Valuation VERU (Veru)|Market Value TPST|Market Value Xilio XLO|Renovaro Inc. (RENB) - Market Value|MURA - Market Value|Market Capitalization Kairos Pharma KAPA|OKUR (OnKure Therapeutics) - Market Valuation|Market Value CytoMed (GDTC)|Market Value Curis|Market Value APLM|Market Value tharimmune.com (THAR)|Market Valuation Advanced Biomed ADVB|Genprex, Inc - Market Valuation|Market Value CLDI|sunshinebiopharma.com - Market Capitalization|Market Value XBIO (xeneticbio.com)|SLRX (Salarius Pharmaceuticals) - Market Valuation|PPBT - Market Capitalization|Market Value American Oncology Network Inc|BGNE (BeiGene) - Market Value|Market Valuation CKPT (Checkpoint Therapeutics, Inc)|ELEV - Market Value|Market Capitalization ICAD (iCAD Inc.)|Ikena (IKNA) - Market Value|NTBL: Market Valuation|VIRX - Market Capitalization|MorphoSys Corp (MOR) - Market Value|Market Valuation NAYA Bio|Market Value Ascentage Pharma Group